Pfizer Buys Wyeth and Cuts Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Buys Wyeth and Cuts Jobs


ePT--the Electronic Newsletter of Pharmaceutical Technology

New York (Jan. 26)—Pfizer will purchase Wyeth (Madison, NJ) under a definitive merger agreement approved by both companies’ boards of directors. The deal is valued at $50.19 per share, or about $68 billion total. The transaction will be financed through cash, debt, and stock. A group of banks committed to finance a total of $22.5 billion in debt.

The combined entity will be one of the most diversified companies in the global healthcare industry, according to a Pfizer press release. The drugmaker predicts that no medicine will account for more than 10% of the combined company’s revenue in 2012. The transaction enhances Pfizer’s product portfolio and, with the acquisition of biopharmaceuticals such as the “Enbrel” arthritis treatment and the “Prevnar” pneumococcal vaccine, reduces its dependence on small molecules. The combined company will have products marketed in several growing therapeutic areas, a strong product pipeline, increased scientific and manufacturing capabilities, and a global presence.

The acquisition of Wyeth will save the combined company roughly $4 billion, according to a Pfizer press release. Pfizer also expects the merger to increase its adjusted diluted earnings per share (EPS) in the second full year after closing. The company’s reported diluted EPS for the fourth quarter of 2008 were $0.04, a 90% reduction from the $0.40 in the fourth quarter of 2007. The loss reflects a $2.3-billion charge to resolve investigations into the company’s off-label marketing practices.

Pfizer also announced a new cost-reduction initiative that is expected to save it approximately $3 billion by the end of 2011. The initiative will entail a 10% reduction in the company’s workforce, including positions in sales, manufacturing, research and development, and informational and administrative organizations. This reduction follows the elimination of 4700 positions in 2008, about 6% of Pfizer’s total workforce. In addition, Pfizer plans to reduce its number of manufacturing sites from 46 to 41. Pfizer expects to incur costs of approximately $6 billion on a pretax basis resulting from this program.

As the merger was announced, Wyeth withdrew from discussions with Dutch biopharmaceutical company Crucell (Leiden, The Netherlands), according to a statement on Crucell’s website. The two companies had been in “friendly discussions” regarding a possible merger, as reported in the Jan. 15, 2009 issue of ePT.

The Pfizer–Wyeth merger reflects the current industrywide focus on biopharmaceuticals. Another recent example, reported in ePT, is the joint venture that Teva Pharmaceutical Industries (Jerusalem) and Lonza Group (Basel) formed on Jan. 20, 2009. The companies will collaborate to develop, manufacture, and market several affordable and safe biosimilars. The joint venture is scheduled to begin during the first quarter of 2009, subject to regulatory approvals. Teva and Lonza expect their partnership to help them secure a leading position in the emerging biosimilars market, according to a Teva press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here